Biotech China 2014

Leukemia: The Mayo Clinic

Total Score People Score Events Score
52 37 12
Date Event Presentation Speakers
May 31, 2013 ASCO Annual Meeting 2013 What's New and Improved in the Care of Children with Rhabdomyosarcoma? Carola A. S. Arndt
Responding to Common Concerns of Patients with Cancer: What's New—In a Nutshell—From Research to Therapeutic Strategies Charles L. Loprinzi
Uncommon Lymphoproliferative Disorders (C01) Angela Dispenzieri
Rationally Combining Targeted and Pathway-Specific Agents Edith A Perez
Special Session David P Steensma
Education Sessions Gloria M. Petersen
April 6, 2013 AACR Annual Meetings Targeting Lymphoid Malignancies: Working from the Outside In Co-Chairpersons: John P. Leonard, Weill Cornell Medical Center, New York, NY, and John C. Byrd, The Ohio State University Comprehensive Cancer Center, Columbus, OH James R. Cerhan
Endocrine Resistance in Breast Cancer Chairperson: Nancy E. Davidson, University of Pittsburgh Cancer Institute, Pittsburgh, PA Matthew P . Goetz
DNA Damage Response: What Do We Know Now and What Will We Learn Next? Chairperson: Junjie Chen, The University of Texas MD Anderson Cancer Center, Houston, TX Junjie Chen
Genetic Epidemiology of Pancreatic Cancer Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN Gloria M. Petersen
August 3, 2011 21st Annual Mayo Clinic Hematology/Oncology Reviews What is New in the Treatment of Hepatobiliary Malignancies Steven R. Alberts
Role of Proton Therapy in GI Malignancies Jonathan Ashman
Management of Metastatic Colorectal Cancer Beyond First-line Therapy George Kim
Recent Advances in the Management of Neuroendocrine Tumors Michaela Banck
GI Cancers Steven R. Alberts
Update of the Oxford Meta-Analysis Adjuvant Data Edith A Perez
What is New on the Management of Triple Negative Breast Cancer Alvaro Moreno-Aspitia
Advances in Breast Cancer Surgery Sarah McLaughlin
Breast Cancer Alvaro Moreno-Aspitia
An Update on Thrombosis Aneel A. Ashrani
Management of ITP Pierre Noel
Benign Hematology Ruben A Mesa
What is New on the Treatment of Prostate Cancer Manish Kohli
Recent Developments in the Management of Sarcomas Gary Schwartz
What is New on the Management of Non-Hodgkin’s Lymphomas Thomas Habermann
What is New on the Management of Myelodysplastic Syndromes David P Steensma
What is New on the Management of Acute Myelogenous Leukemia’s James Foran
What is New on the Management of Chronic Myeloproliferative DisordersMesa Ruben A Mesa
Hematological Malignancies Ruben A Mesa
February 17, 2011 15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma Promising New Drugs in Clinical Trials in Myeloma Keith Stewart
CON Keith Stewart
How I Treat Myelofibrosis If No Clinical Trial Is Available Ruben A Mesa
Multiple Myeloma Keith Stewart
Chronic Myeloid Leukemia | Myeloproliferative Neoplasms Ruben A Mesa
September 11, 2010 New Advances in Inflammatory Bowel Disease Q&A / Panel Discussion William J. Tremaine
Prebiotics, Biotics and Probiotics: Is There a Role in the Treatment of IBD? William J. Tremaine
April 30, 2010 Great Debates and Updates in Hematologic Malignancies Debate: For newly diagnosed SCTeligible myeloma patients the most appropriate induction therapy is: Shaji Kumar
Debate: What is the most appropriate frontline regimen for transplant ineligible myeloma patients? S. Vincent Rajkumar
Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed multiple myeloma patients? S. Vincent Rajkumar
Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia? Shaji Kumar
Debate: For newly diagnosed multiple myeloma patients who relapse from a ≥VGPR response more than 12 months following frontline therapy, what is the best salvage strategy? Rafael Fonseca
How I manage multiple myeloma patients who present with significant pre-existing illnesses or serious complications of the myeloma: S. Vincent Rajkumar, Shaji Kumar, Rafael Fonseca
What is the role of allogeneic transplantation in myeloproliferative neoplasms Ruben A Mesa
How I deal with the difficult questions in the management of Essential Thrombocythemia Ruben A Mesa
January 22, 2010 Highlights of American Society of Hematology® Panel Discussion: Neil E. Kay
Chronic Lymphocytic Leukemia: Novel Therapies Neil E. Kay
Panel Discussion: Keith Stewart
Myeloma Keith Stewart
September 11, 2009 Sixth Annual Symposium on Controversies and Clinical Challenges In Lymphoma, Myeloma, and Leukemia Clinical Challenges in TCLs Barbara Pro
Clinical Challenges in Treating Patients With MPDs Ruben A Mesa
Timing of Transplant Shaji Kumar
Complete Response and Clinical Benefit P. Leif Bergsagel
Cytogenetics, Prognosis, and New Therapies in MM Keith Stewart
Management of Relapsed Myeloma Shaji Kumar
Keynote Presentation: Integrated Therapies: A View From the Bench Rafael Fonseca
Clinical Challenges in CML Resistant to TKIs Ruben A Mesa
June 27, 2008 American Society of Clinical Oncology Program Commitee P Leif Bergsagel, Edith A Perez
May 30, 2008 ASCO Annual'08 Meeting breast cancer-- Developmental Therapeutic Approaches to Triple-Negative Breast Cancer Edith A Perez
developmental therapeutics-- Developmental Therapeutic Approaches to Triple-Negative Breast Cancer Edith A Perez
gastrointestinal (noncolorectal) cancer-- Multimodality Treatment of Bile Duct Tumors (M14) Steven R. Alberts
leukemia, myelodysplasia, and transplantation-- Myeloproliferative Disorders at the Cutting Edge Ayalew Tefferi
lymphoma and plasma cell disorders-- Initial Therapy for Multiple Myeloma: Considerations for an Integrated Risk- Adapted Approach S. Vincent Rajkumar
meet the professor sessions-- Multimodality Treatment of Bile Duct Tumors (M14) Steven R. Alberts
October 11, 2007 Sixth International Colorectal Cancer Congress Continuous vs. Intermittent Treatment Axel Grothey
Roundtable Discussion: Should There Be Planned Chemoholidays? Axel Grothey
How Long Do We Need to Treat Patients in the Adjuvant Setting? Axel Grothey
Moving EGFR Inhibitors to the Front-line and Further: Are We Ready Yet? Axel Grothey
North Central Cancer Treatment Group Steven R. Alberts
Ongoing Clinical Trials of Antiangiogenic Agents Axel Grothey
Should Anti-VEGF Therapy Continue Beyond Progession? Axel Grothey
Neoadjuvant Therapy Options and Duration: To Best Response or Resectability? Steven R. Alberts
Biomarker-Driven Trial Designs Daniel Sargent
Have We Maxed Out the Effect of PFS in First-line Therapy? Daniel Sargent, Axel Grothey
Novel VEGFR Inhibitors in Colorectal Cancer Alex A Adjei
Multidisciplinary Management for Timing of Rectal Surgery Axel Grothey
July 21, 2007 Hematopoietic Malignancies Oncogene activation in the germinal center is the primary determinant of MM disease phenotype” Leif Bergsagel
A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma Marta Chesi
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.